Jianbing B. Wu

No. 1, Minde Road
Nanchang, 330006, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

SERPINE2-mediated activation of JAK2/STAT3 facilitates NRF2 nuclear translocation and GCLC transcription to confer ferroptosis resistance and lenvatinib resistance in hepatocellular carcinoma.

SERPINE2-mediated activation of JAK2/STAT3 facilitates NRF2 nuclear translocation and GCLC transcription to confer ferroptosis resistance and lenvatinib resistance in hepatocellular carcinoma.

Journal: Journal of experimental & clinical cancer research : CR

Published: February 28, 2026

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.

Journal: Clinical and experimental medicine

Published: February 13, 2026

Identification of a Prognostic Gene Signature Based on Lenvatinib Resistance in Hepatocellular Carcinoma with Functional Validation of the Key Gene CPB2.

Identification of a Prognostic Gene Signature Based on Lenvatinib Resistance in Hepatocellular Carcinoma with Functional Validation of the Key Gene CPB2.

Journal: Journal of hepatocellular carcinoma

Published: January 08, 2026

Low-Dose Versus Standard-Dose Bevacizumab Plus Sintilimab for Unresectable Hepatocellular Carcinoma: A Real-World Comparative Study of Efficacy and Safety.

Low-Dose Versus Standard-Dose Bevacizumab Plus Sintilimab for Unresectable Hepatocellular Carcinoma: A Real-World Comparative Study of Efficacy and Safety.

Journal: Journal of hepatocellular carcinoma

Published: November 20, 2025

Safety and efficacy of PD-1/PD-L1 inhibitors combined with albumin-bound paclitaxel and fluorouracil-based agents as second-line therapy in biliary tract cancers.

Safety and efficacy of PD-1/PD-L1 inhibitors combined with albumin-bound paclitaxel and fluorouracil-based agents as second-line therapy in biliary tract cancers.

Journal: World journal of surgical oncology

Published: November 19, 2025

Author Correction: hsa_circ_0008305 facilitates the malignant progression of hepatocellular carcinoma by regulating AKR1C3 expression and sponging miR-379-5p.

Author Correction: hsa_circ_0008305 facilitates the malignant progression of hepatocellular carcinoma by regulating AKR1C3 expression and sponging miR-379-5p.

Journal: Scientific reports

Published: September 02, 2025

Establishment and Validation of a Novel Nutritional-Immune-Inflammatory Score Model for Predicting Survival Prognosis in Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.

Establishment and Validation of a Novel Nutritional-Immune-Inflammatory Score Model for Predicting Survival Prognosis in Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.

Journal: Journal of inflammation research

Published: June 11, 2025

DDX1 facilitates lenvatinib resistance in hepatocellular carcinoma through regulating ephrin-A3 and activating the Wnt/β-catenin signaling pathway.

DDX1 facilitates lenvatinib resistance in hepatocellular carcinoma through regulating ephrin-A3 and activating the Wnt/β-catenin signaling pathway.

Journal: Functional & integrative genomics

Published: May 06, 2025

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.

Journal: Signal transduction and targeted therapy

Published: January 18, 2025

Transarterial Chemoembolization plus Sorafenib versus Sorafenib Alone in Advanced Hepatocellular Carcinoma (SELECT): A Multicenter, Phase 3, Randomized, Controlled Trial.

Transarterial Chemoembolization plus Sorafenib versus Sorafenib Alone in Advanced Hepatocellular Carcinoma (SELECT): A Multicenter, Phase 3, Randomized, Controlled Trial.

Journal: Liver cancer

Published: January 08, 2025

Systematic pan-cancer analysis identifies PKNOX1 as a potential prognostic and immunological biomarker and its functional validation.

Systematic pan-cancer analysis identifies PKNOX1 as a potential prognostic and immunological biomarker and its functional validation.

Journal: Frontiers in immunology

Published: November 24, 2024

Comparative efficacy of tislelizumab plus lenvatinib and tislelizumab alone against advanced hepatocellular carcinoma after lenvatinib failure: a real-world study.

Comparative efficacy of tislelizumab plus lenvatinib and tislelizumab alone against advanced hepatocellular carcinoma after lenvatinib failure: a real-world study.

Journal: BMC cancer

Published: November 20, 2024

Showing 1-12 of 46

Last Updated: 09/26/2026